WEDNESDAY 13th JULY 2016 COMMENCING 09:30 AM
AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF CAMPUS,
WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Chairman’s report

6. Appraisal 1: Full Submission
Ceftolozane/tazobactam (Zerbaxa®) for the treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents

7. Appraisal 2: Limited Submission
Aprepitant (EMEND®) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from the age of 6 months to less than 18 years old. Aprepitant is given as part of combination therapy

To protect commercial confidentiality the following appraisals will be held in private and the meeting will close to the public

8. Appraisal 3: Full Submission (WPAS)
Blinatumomab (Blincyto®) for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia

9. Appraisal 4: Full Submission (WPAS)
Netupitant/palonosetron (Akynzeo®) in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy

Enclosure
1/AWMSG/0716

Appendices
2/AWMSG/0716

Appendices
3/AWMSG/0716

Appendices
4/AWMSG/0716

Appendices
5/AWMSG/0716

Appendices
10. **Appraisal 5: Full Submission (WPAS)**
    *Lenalidomide (Revlimid®)* for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant

11. **Appraisal 6: Limited Submission (WPAS)**
    *Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®)* for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir

**Date of next meeting:** 21st September 2016 in Abergavenny